サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1711067

次世代薬剤複合体の世界市場レポート 2025年

Next Generation Drug Conjugates Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
次世代薬剤複合体の世界市場レポート 2025年
出版日: 2025年04月03日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

次世代薬剤複合体の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR16.0%で45億3,000万米ドルに成長します。予測期間の成長は、併用療法の成長、臨床研究の拡大、希少疾患への注力、戦略的共同研究、バイオインフォマティクスツールの台頭などに起因すると考えられます。予測期間における主要動向としては、モノクローナル抗体技術の進歩、JAK阻害剤との併用療法、医薬品開発における人工知能、バイオシミラーの開発、皮下製剤の進歩などが挙げられます。

がんの有病率の増加は、将来的に次世代薬剤結合体市場の成長を促進すると予想されます。がんは、体内の異常細胞の制御不能な増殖と拡散を特徴とする疾患群を包含します。がん患者の増加は、人口の高齢化、ライフスタイルの選択、環境暴露、検出の進歩、遺伝的素因、感染因子など、いくつかの要因に起因しています。次世代ドラッグコンジュゲートは、標的治療をがん細胞に直接送達することで治療効果を高めつつ、健康な組織への害を最小限に抑え、がんと闘うことを目的としています。例えば、2024年8月、オーストラリアの医療福祉統計に特化した国家機関であるオーストラリア保健福祉ラボの報告書によると、2034年までにオーストラリアで新たにがんと診断される患者数は約20万9,000人となり、2024年に予想された16万9,000人から増加すると予測されました。この増加は、人口増加とがん罹患率の上昇の影響を反映しています。したがって、がんの有病率の上昇が次世代薬剤結合体市場の成長を後押ししています。

次世代薬剤複合体市場の主要参入企業は、研究開発能力の強化、製品イノベーションの加速、市場でのプレゼンス拡大のために戦略的提携を進めています。戦略的パートナーシップは、企業が互いの強みとリソースを活用し、相互利益と成功を目指すものです。例えば、2023年11月、米国を拠点とする臨床段階の高精度がん治療企業であるプレリュード・セラピューティクスインコーポレイテッドは、カナダのバイオテクノロジー企業であるアブセラ・バイオロジクスインコーポレイテッドと提携し、この提携は、革新的なADCの発見、開発、商業化に重点を置くもので、新規抗体と結合したSMARCA分解物を対象とするプログラムから開始されます。この戦略の目標は、プレリュードの低分子SMARCA2選択的分解剤の治療応用を、より幅広い患者集団、特にSMARCA4変異を伴わないがん患者集団に拡大することです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の次世代薬剤複合体PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の次世代薬剤複合体市場：成長率分析
  • 世界の次世代薬剤複合体市場の実績：規模と成長、2019～2024年
  • 世界の次世代薬剤複合体市場の予測：規模と成長、2024～2029年、2034年
  • 世界の次世代薬剤複合体総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の次世代薬剤複合体市場：次世代薬剤複合体タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ペプチド受容体放射性核種療法
  • リガンド媒介RNAI複合体
  • リガンド結合型抗センス医薬品
  • ペプチド薬剤複合体
  • 世界の次世代薬剤複合体市場：リガンドタイプ対象別、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • アミノシュガー
  • 脂質
  • ペプチド
  • 小分子
  • ウイルス様粒子
  • 世界の次世代薬剤複合体市場：ペイロードタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • オリゴヌクレオチド
  • 放射性核種
  • ペプチド
  • 小分子
  • 世界の次世代薬剤複合体市場：療法別、実績と予測、2019～2024年、2024～2029年、2034年
  • 単剤療法
  • 併用療法
  • 世界の次世代薬剤複合体市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
  • 消化管膵神経内分泌腫瘍
  • 前立腺がん
  • 乳がんの脳転移によって引き起こされる軟膜がん腫症
  • 遺伝性トランスサイレチンアミロイドーシス
  • 動脈硬化性心血管疾患
  • 重度の高トリグリセリド血症
  • 遺伝性血管性浮腫
  • 急性肝性ポルフィリン症
  • その他
  • 世界の次世代薬剤複合体市場、ペプチド受容体放射性核種療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ソマトスタチン類似体
  • 放射性標識ペプチド
  • 世界の次世代薬剤複合体市場、リガンド媒介RNAi複合体のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • SiRNAリガンドコンジュゲート
  • ShRNAリガンドコンジュゲート
  • 世界の次世代薬剤複合体市場、リガンド結合型抗センス医薬品のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • オリゴヌクレオチドリガンドコンジュゲート
  • アンチセンスオリゴヌクレオチドリガンドコンジュゲート
  • 世界の次世代薬剤複合体市場、ペプチド薬剤複合体のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 細胞傷害性ペプチド複合体
  • 治療用ペプチド複合体

第7章 地域別・国別分析

  • 世界の次世代薬剤複合体市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の次世代薬剤複合体市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 次世代薬剤複合体市場：競合情勢
  • 次世代薬剤複合体市場：企業プロファイル
    • Pfizer Inc.
    • Johnson & Johnson
    • Merck & Co. Inc.
    • AbbVie Inc.
    • Novartis International AG

第31章 その他の大手企業と革新的企業

  • AstraZeneca PLC
  • Daiichi Sankyo Company Limited
  • Eisai Co Ltd.
  • Bicycle Therapeutics plc
  • Zymeworks Inc.
  • Genentech Inc.
  • MacroGenics Inc.
  • Abzena plc
  • Innate Pharma S.A.
  • CytomX Therapeutics Inc.
  • ImmunoGen Inc.
  • Ascentage Pharma Group International
  • Mersana Therapeutics Inc.
  • Antengene Corporation Limited
  • Nurix Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

  • 次世代薬剤複合体市場、2029年：新たな機会を提供する国
  • 次世代薬剤複合体市場、2029年：新たな機会を提供するセグメント
  • 次世代薬剤複合体市場、2029年：成長戦略
    • 市場動向による戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r32092

Next-generation drug conjugates refer to advanced formulations designed to enhance the efficacy and safety of targeted therapies. These drug conjugates employ cutting-edge targeting technologies and improved payloads to deliver powerful treatments directly to disease cells with greater precision and fewer side effects.

The main types of next-generation drug conjugates include peptide receptor radionuclide therapy, ligand-mediated RNAi conjugates, ligand-conjugated antisense medicines, and peptide drug conjugates. Peptide Receptor Radionuclide Therapy (PRRT) is a targeted cancer treatment that utilizes radioactive peptides to bind to and destroy tumor cells that express specific receptors. The targeting ligands consist of amino sugars, lipids, peptides, small molecules, and virus-like particles, while the payloads include oligonucleotides, radionuclides, peptides, and small molecules. This therapy can be administered as either a monotherapy or in combination with other treatments for various indications, including gastroenteropancreatic neuroendocrine tumors, prostate cancer, leptomeningeal carcinomatosis due to breast cancer brain metastases, hereditary transthyretin amyloidosis, atherosclerotic cardiovascular diseases, severe hypertriglyceridemia, hereditary angioedema, acute hepatic porphyria, and more.

The next-generation drug conjugates market research report is one of a series of new reports from The Business Research Company that provides next-generation drug conjugates market statistics, including the next-generation drug conjugates industry's global market size, regional shares, competitors with a next-generation drug conjugates market share, detailed next-generation drug conjugates market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation drug conjugates industry. This next-generation drug conjugates market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The next generation drug conjugates market size has grown rapidly in recent years. It will grow from $2.15 billion in 2024 to $2.5 billion in 2025 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to an increasing understanding of tumor biology, the success of early drug conjugates, increasing oncology, increasing investment and funding, and increasing patient advocacy and awareness.

The next generation drug conjugates market size is expected to see rapid growth in the next few years. It will grow to $4.53 billion in 2029 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period can be attributed to the growth of combination therapies, clinical research expansion, focus on rare diseases, strategic collaborations, and emerging bioinformatics tools. Major trends in the forecast period include advancements in monoclonal antibody technology, combination therapies with JAK inhibitors, artificial intelligence in drug development, development of biosimilars, and advancements in subcutaneous formulations.

The increasing prevalence of cancer is anticipated to drive the growth of the next-generation drug conjugates market in the future. Cancer encompasses a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The rise in cancer cases can be attributed to several factors, including an aging population, lifestyle choices, environmental exposures, advancements in detection, genetic predispositions, and infectious agents. Next-generation drug conjugates aim to combat cancer by delivering targeted therapies directly to cancer cells, thereby enhancing treatment effectiveness while minimizing harm to healthy tissues. For example, in August 2024, a report by the Australian Institute of Health and Welfare, a national agency focused on health and welfare statistics in Australia, projected that by 2034, the country would see approximately 209,000 new cancer diagnoses, up from an estimated 169,000 cases expected in 2024. This increase reflects the impact of a growing population and rising cancer rates. Hence, the escalating prevalence of cancer is propelling the growth of the next-generation drug conjugates market.

Key players in the next-generation drug conjugates market are pursuing strategic partnerships to enhance research and development capabilities, accelerate product innovation, and expand their market presence. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits and success. For instance, in November 2023, Prelude Therapeutics Incorporated, a U.S.-based clinical-stage precision oncology company, entered into a partnership with AbCellera Biologics Inc., a Canadian biotechnology firm, to develop first-in-class precision antibody-drug conjugates (ADCs) for oncology applications. This collaboration will focus on the discovery, development, and commercialization of innovative ADCs, beginning with a program targeting a SMARCA degrader linked to a novel antibody. The goal of this strategy is to expand the therapeutic applications of Prelude's small-molecule SMARCA2 selective degraders to a broader patient population, particularly those with cancers not associated with SMARCA4 mutations.

In March 2024, Johnson & Johnson, a U.S.-based pharmaceutical and medical device manufacturer, acquired Ambrx Biopharma for $2 billion. This acquisition aims to strengthen Johnson & Johnson's oncology portfolio and further the development of next-generation antibody-drug conjugates designed to transform cancer treatment. Ambrx Biopharma is a clinical-stage biopharmaceutical company in the U.S. specializing in next-generation drug conjugates.

Major companies operating in the next generation drug conjugates market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH

North America was the largest region in the next generation drug conjugates market in 2023. The regions covered in the next generation drug conjugates marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the next generation drug conjugates marker report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next-generation drug conjugates market consists of revenues earned by entities by providing services such as targeted cancer therapies, gene therapy conjugates, and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation drug conjugates market also includes sales of small molecule drug conjugates, RNA-targeted conjugates, and enzyme-linked drug conjugates. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next Generation Drug Conjugates Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next generation drug conjugates market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next generation drug conjugates ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The next generation drug conjugates market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy; Ligand Mediated RNAI Conjugate; Ligand Conjugated Anti Sense Medicine; Peptide Drug Conjugate
  • 2) By Targeting Ligand Type: Amino Sugar; Lipid; Peptide; Small Molecule; Virus-Like Particles
  • 3) By Payload Type: Oligonucleotide; Radionuclide; Peptide; Small Molecule
  • 4) By Therapy: Monotherapy; Combination Therapy
  • 5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors; Prostate Cancer; Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases; Hereditary Transthyretin Amyloidosis; Atherosclerotic Cardiovascular Diseases; Severe Hypertriglyceridemia; Hereditary Angioedema; Acute Hepatic Porphyria; Other Indications
  • Subsegments:
  • 1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues; Radiolabeled Peptides
  • 2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates; ShRNA Ligand Conjugates
  • 3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates; Antisense Oligonucleotide Ligand Conjugates
  • 4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates; Therapeutic Peptide Conjugates
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Novartis International AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Next Generation Drug Conjugates Market Characteristics

3. Next Generation Drug Conjugates Market Trends And Strategies

4. Next Generation Drug Conjugates Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Next Generation Drug Conjugates Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Next Generation Drug Conjugates PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Next Generation Drug Conjugates Market Growth Rate Analysis
  • 5.4. Global Next Generation Drug Conjugates Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Next Generation Drug Conjugates Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Next Generation Drug Conjugates Total Addressable Market (TAM)

6. Next Generation Drug Conjugates Market Segmentation

  • 6.1. Global Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Peptide Receptor Radionuclide Therapy
  • Ligand Mediated RNAI Conjugate
  • Ligand Conjugated Anti Sense Medicine
  • Peptide Drug Conjugate
  • 6.2. Global Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Amino Sugar
  • Lipid
  • Peptide
  • Small Molecule
  • Virus-Like Particles
  • 6.3. Global Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oligonucleotide
  • Radionuclide
  • Peptide
  • Small Molecule
  • 6.4. Global Next Generation Drug Conjugates Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Monotherapy
  • Combination Therapy
  • 6.5. Global Next Generation Drug Conjugates Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gastroenteropancreatic Neuroendocrine Tumors
  • Prostate Cancer
  • Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases
  • Hereditary Transthyretin Amyloidosis
  • Atherosclerotic Cardiovascular Diseases
  • Severe Hypertriglyceridemia
  • Hereditary Angioedema
  • Acute Hepatic Porphyria
  • Other Indications
  • 6.6. Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Peptide Receptor Radionuclide Therapy (PRRT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Somatostatin Analogues
  • Radiolabeled Peptides
  • 6.7. Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Ligand Mediated RNAi Conjugate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • SiRNA Ligand Conjugates
  • ShRNA Ligand Conjugates
  • 6.8. Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Ligand Conjugated Anti-Sense Medicine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oligonucleotide Ligand Conjugates
  • Antisense Oligonucleotide Ligand Conjugates
  • 6.9. Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Peptide Drug Conjugate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cytotoxic Peptide Conjugates
  • Therapeutic Peptide Conjugates

7. Next Generation Drug Conjugates Market Regional And Country Analysis

  • 7.1. Global Next Generation Drug Conjugates Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Next Generation Drug Conjugates Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Next Generation Drug Conjugates Market

  • 8.1. Asia-Pacific Next Generation Drug Conjugates Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Next Generation Drug Conjugates Market

  • 9.1. China Next Generation Drug Conjugates Market Overview
  • 9.2. China Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Next Generation Drug Conjugates Market

  • 10.1. India Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Next Generation Drug Conjugates Market

  • 11.1. Japan Next Generation Drug Conjugates Market Overview
  • 11.2. Japan Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Next Generation Drug Conjugates Market

  • 12.1. Australia Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Next Generation Drug Conjugates Market

  • 13.1. Indonesia Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Next Generation Drug Conjugates Market

  • 14.1. South Korea Next Generation Drug Conjugates Market Overview
  • 14.2. South Korea Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Next Generation Drug Conjugates Market

  • 15.1. Western Europe Next Generation Drug Conjugates Market Overview
  • 15.2. Western Europe Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Next Generation Drug Conjugates Market

  • 16.1. UK Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Next Generation Drug Conjugates Market

  • 17.1. Germany Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Next Generation Drug Conjugates Market

  • 18.1. France Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Next Generation Drug Conjugates Market

  • 19.1. Italy Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Next Generation Drug Conjugates Market

  • 20.1. Spain Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Next Generation Drug Conjugates Market

  • 21.1. Eastern Europe Next Generation Drug Conjugates Market Overview
  • 21.2. Eastern Europe Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Next Generation Drug Conjugates Market

  • 22.1. Russia Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Next Generation Drug Conjugates Market

  • 23.1. North America Next Generation Drug Conjugates Market Overview
  • 23.2. North America Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Next Generation Drug Conjugates Market

  • 24.1. USA Next Generation Drug Conjugates Market Overview
  • 24.2. USA Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Next Generation Drug Conjugates Market

  • 25.1. Canada Next Generation Drug Conjugates Market Overview
  • 25.2. Canada Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Next Generation Drug Conjugates Market

  • 26.1. South America Next Generation Drug Conjugates Market Overview
  • 26.2. South America Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Next Generation Drug Conjugates Market

  • 27.1. Brazil Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Next Generation Drug Conjugates Market

  • 28.1. Middle East Next Generation Drug Conjugates Market Overview
  • 28.2. Middle East Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Next Generation Drug Conjugates Market

  • 29.1. Africa Next Generation Drug Conjugates Market Overview
  • 29.2. Africa Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Next Generation Drug Conjugates Market Competitive Landscape And Company Profiles

  • 30.1. Next Generation Drug Conjugates Market Competitive Landscape
  • 30.2. Next Generation Drug Conjugates Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

31. Next Generation Drug Conjugates Market Other Major And Innovative Companies

  • 31.1. AstraZeneca PLC
  • 31.2. Daiichi Sankyo Company Limited
  • 31.3. Eisai Co Ltd.
  • 31.4. Bicycle Therapeutics plc
  • 31.5. Zymeworks Inc.
  • 31.6. Genentech Inc.
  • 31.7. MacroGenics Inc.
  • 31.8. Abzena plc
  • 31.9. Innate Pharma S.A.
  • 31.10. CytomX Therapeutics Inc.
  • 31.11. ImmunoGen Inc.
  • 31.12. Ascentage Pharma Group International
  • 31.13. Mersana Therapeutics Inc.
  • 31.14. Antengene Corporation Limited
  • 31.15. Nurix Therapeutics Inc.

32. Global Next Generation Drug Conjugates Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next Generation Drug Conjugates Market

34. Recent Developments In The Next Generation Drug Conjugates Market

35. Next Generation Drug Conjugates Market High Potential Countries, Segments and Strategies

  • 35.1 Next Generation Drug Conjugates Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Next Generation Drug Conjugates Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Next Generation Drug Conjugates Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer